American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: http://www.sciepub.com/journal/ajmcr Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
American Journal of Medical Case Reports. 2016, 4(1), 16-18
DOI: 10.12691/ajmcr-4-1-5
Open AccessArticle

A Case of Periprocedural Discontinuation of Apixaban Resulting in Intra-aortic Thrombosis

Sabu John1, Pramod Theetha Kariyanna2, , Jonathan Marmur1, Kamal Preet Singh1 and Mary Mallappallil1

1Division of Cardiology, Department of Internal Medicine, State University of New York, Downstate Medical Center, Brooklyn, New York, U.S.A.

2Department of Internal Medicine, State University of New York, Downstate Medical Center, Brooklyn, New York, U.S.A.

Pub. Date: January 21, 2016

Cite this paper:
Sabu John, Pramod Theetha Kariyanna, Jonathan Marmur, Kamal Preet Singh and Mary Mallappallil. A Case of Periprocedural Discontinuation of Apixaban Resulting in Intra-aortic Thrombosis. American Journal of Medical Case Reports. 2016; 4(1):16-18. doi: 10.12691/ajmcr-4-1-5

Abstract

Apixaban, a novel oral anticoagulant is approved for anticoagulation in non-valvular atrial fibrillation. Apixaban is found to be superior to warfarin in prevention of stroke and thromboembolism and is associated with lesser risk of bleeding. Peri-procedural discontinuation of apixaban is safe, but the risk of thrombosis exists. We here present a case of arterial thrombosis that lead to lower limb ischemia upon periprocedural discontinuation of apixaban.

Keywords:
apixaban anticoagulation non-valvular atrial fibrillation thrombosis

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 1

References:

[1]  U.S. Food and Drug Administration, Eliquis (apixaban) tablets, Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER), September 2015. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm384790.htm.
 
[2]  Bristol-Myers Squibb Pfizer, Eliquis (apixaban), August 2015. http://www.eliquis.bmscustomerconnect.com/.
 
[3]  Granger, C.B., Alexander, J. H., McMurray, J.J.V., Lopes, R.D., Hylek, E.M., Hanna, M., Al-Khalidi, H.R., Ansell, J., Atar, D., Avezum, A., Bahit, M.C., Diaz, R., Easton, J.D., Ezekowitz, J.A., Flaker, G., Garcia,.D., Geraldes, M., Gersh, B.J., Golitsyn, S., Goto, S., Hermosillo,A.G., Hohnloser, S.H., Horowitz, J., Mohan, P., Jansky, P., Lewis, B.S., Lopez-Sendon, J.L., Pais, P., Parkhomenko, A., Verheugt, F.W.A., Zhu, J., and Wallentin, L. for the ARISTOTLE Committees and Investigators, Apixaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, 365. 981-992. September 2011.
 
[4]  Wang, L., Raghavan, N., He, K., Luettgen, J.M., Humphreys, W.G.,. Knabb, R.M., Pinto, D.J., and Zhan, D, Sulfation of O-Demethyl Apixaban: Enzyme Identification and Species Comparison, Drug metabolism and disposition, 37. 802–808. January 2009.
 
[5]  Tran,H., Joseph, J., Young, L., McRae, S., Curnow, J., Nandurkar, H., Wood, P., and McLintock, C., New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management, Internal Medicine Journal, 44. 525-536, March 2014.
 
[6]  Douxfils, J., Chatelain, C., Chatelain, B., Dogne, J.M., and Mullier, F., Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide, Thrombosis and Haemostasis. 110 (2). 283-392. August 2013.
 
[7]  Garcia, D., Alexander, J.H., Wallentin, L., Wojdyla, D.M., Thomas, L., Hanna, M., Al-Khatib, S.M., Dorian, P., Ansell, J., Commerford P., Flaker, G., Lanas, F.,Vinereanu, D., Xavier, D., Hylek, E.M., Held, C., Verheugt, F.W., Granger, C. B., and Lopes, R. D., Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures, Blood. 124(25). 3692-3688. December 2014.
 
[8]  Llau, J.V., Ferrandis, R., Castillo, J., De Andrés, J., Gomar, C., Gómez-Luque, A., Hidalgo, F., and Torres. L.M., Management of direct action oral anticoagulants in the peri-operative period and invasive techniques, Revista Espanola de Anesresiologia y Reanimacion, 59(6). 321-330. June-July 2012.
 
[9]  Sié, P., Samama, C.M., Godier, A., Rosencher, N., Steib, A., Llau, J.V., Van der Linden, P., Pernod, G., Lecompte, T., Gouin-Thibault, I., and Albaladejo, P., Working Group on Perioperative Haemostasis; French Study Group on Thrombosis and Haemostasis, Archives of Cardiovascular Diseases, 104(12). 669-676. December 2011.
 
[10]  Baron, H.T., Kamath, P.S.., and McBane, R.D., Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures, New England Journal of Medicine, 368. 2113-2124. May 2013.